

## NEWS RELEASE

*Solasia*

### **Notice of Review Progress of episil<sup>®</sup> oral liquid in China**

Tokyo, Japan, February 4, 2019 - Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") announced that the review for the New Medical Device Approval of episil<sup>®</sup> oral liquid (SP-03) at the Center for Medical Device Evaluation (CMDE) has been completed and presented to the National Medical Products Administration (NMPA, formerly CFDA or CNDA).

\*\*\*\*\*

#### **About Solasia:**

Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.

Additional information is available at <http://www.solasia.co.jp/en/>

(Contacts)

**Solasia Pharma K.K.**

Rie Toyoda

Public Relations and Investor Relations

+81-3-5843-8049

info@solasia.co.jp